| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
VP, Chief Accounting Officer | VP, Pao And Interim Pfo
1 company
Dube Michael P is a VP, Chief Accounting Officer at NTLA. Recent filings cover 0 purchases and 5 sales. Those positions are worth an estimated $628K at current prices.
Our model assigns Dube Michael P a below-average insider score of 45/100, based on 5 past trades. Over a 12-month horizon, 33.3% of those trades were profitable, with an average 12-month return of -16.6%.
Dube Michael P's largest disclosed position is in NTLA as VP, Chief Accounting Officer, worth about $628K. The recent filings there lean toward selling, a net 10,747 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jan 5, 2026 | NTLA Intellia Therapeutics, Inc. | VP, Chief Accounting Officer | Sell | 2,989 | $9.21 | $27,528.69 | -5.4% | +41.9% | - | |
| Oct 1, 2025 | NTLA Intellia Therapeutics, Inc. | VP, Chief Accounting Officer | Sell | 1,871 | $17.38 | $32,517.98 | -3.3% | -51.7% | - | |
| Jul 2, 2025 | NTLA Intellia Therapeutics, Inc. | VP, Chief Accounting Officer | Sell | 2,503 | $9.95 | $24,904.85 | -4.2% | +61.0% | +63.7% | |
| Jan 3, 2025 | NTLA Intellia Therapeutics, Inc. | VP, Chief Accounting Officer | Sell | 1,372 | $12.18 | $16,710.96 | -2.9% | -43.2% | -24.1% | |
| Oct 2, 2024 | NTLA Intellia Therapeutics, Inc. | VP, Chief Accounting Officer | Sell | 2,012 | $19.01 | $38,248.12 | -4.1% | -37.1% | +10.2% |